These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

763 related articles for article (PubMed ID: 27673289)

  • 1. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
    Tewari KS; Eskander RN; Monk BJ
    Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.
    Lorusso D; Tripodi E; Maltese G; Lepori S; Sabatucci I; Bogani G; Raspagliesi F
    Drug Des Devel Ther; 2018; 12():1501-1509. PubMed ID: 29881257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
    Gadducci A; Guerrieri ME
    Anticancer Res; 2016 May; 36(5):2055-64. PubMed ID: 27127105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
    Lheureux S; Bruce JP; Burnier JV; Karakasis K; Shaw PA; Clarke BA; Yang SY; Quevedo R; Li T; Dowar M; Bowering V; Pugh TJ; Oza AM
    J Clin Oncol; 2017 Apr; 35(11):1240-1249. PubMed ID: 28221868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
    Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
    J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
    Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
    Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.
    Nirsimloo R; Gourley C
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):597-603. PubMed ID: 27115428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer.
    De Jaeghere E; Vandecasteele K; Claes K; Makar A; Tummers P; Cocquyt V; Denys H
    Acta Clin Belg; 2017 Feb; 72(1):6-11. PubMed ID: 27267353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaparib for the treatment of epithelial ovarian cancer.
    McLachlan J; Banerjee S
    Expert Opin Pharmacother; 2016; 17(7):995-1003. PubMed ID: 26967466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
    Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
    Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.